Abstract
The androgen receptor (AR) plays a central role in the initiation and growth of prostate cancer. Androgen deprivation therapy (ADT) has been a gold standard for advanced prostate cancer for decades. Unfortunately, suppressive effects of ADT do not last long and hormone-refractory prostate cancer develops within several years. In spite of extensive research on mechanisms of hormone-independent growth of prostate cancer, there are few effective treatment options for recurrent tumors and most patients die from the disease in a short period of time. Accumulating evidence suggests that the AR signaling system remains intact and activated despite low levels of androgens in hormone-resistant prostate cancer. Currently, modifications to the AR via mutations, amplification and phosphorylation have been proposed as underlying mechanisms of hormone-resistance of prostate cancer cells. In addition, changes in AR cofactors are implicated in ligand-independent activation of AR signaling. Thus, the development of novel and more effective treatment modalities targeting the AR and AR-related molecules may provide better management of androgen-independent prostate cancer. Although recent patents on the AR related to prostate cancer are focused on antiandrogens, future trend will be shifted to agents or methods suppressing molecules or pathways that activate AR signaling in low androgen environments.
Keywords: Prostate, neoplasms, androgen, receptor, amplification, phosphorylation, mutation
Recent Patents on Anti-Cancer Drug Discovery
Title: The Androgen Receptor as Putative Therapeutic Target in Hormone-Refractory Prostate Cancer
Volume: 2 Issue: 3
Author(s): Yukio Kageyama, Nobuhiko Hyochi, Kazunori Kihara and Hiroshi Sugiyama
Affiliation:
Keywords: Prostate, neoplasms, androgen, receptor, amplification, phosphorylation, mutation
Abstract: The androgen receptor (AR) plays a central role in the initiation and growth of prostate cancer. Androgen deprivation therapy (ADT) has been a gold standard for advanced prostate cancer for decades. Unfortunately, suppressive effects of ADT do not last long and hormone-refractory prostate cancer develops within several years. In spite of extensive research on mechanisms of hormone-independent growth of prostate cancer, there are few effective treatment options for recurrent tumors and most patients die from the disease in a short period of time. Accumulating evidence suggests that the AR signaling system remains intact and activated despite low levels of androgens in hormone-resistant prostate cancer. Currently, modifications to the AR via mutations, amplification and phosphorylation have been proposed as underlying mechanisms of hormone-resistance of prostate cancer cells. In addition, changes in AR cofactors are implicated in ligand-independent activation of AR signaling. Thus, the development of novel and more effective treatment modalities targeting the AR and AR-related molecules may provide better management of androgen-independent prostate cancer. Although recent patents on the AR related to prostate cancer are focused on antiandrogens, future trend will be shifted to agents or methods suppressing molecules or pathways that activate AR signaling in low androgen environments.
Export Options
About this article
Cite this article as:
Kageyama Yukio, Hyochi Nobuhiko, Kihara Kazunori and Sugiyama Hiroshi, The Androgen Receptor as Putative Therapeutic Target in Hormone-Refractory Prostate Cancer, Recent Patents on Anti-Cancer Drug Discovery 2007; 2 (3) . https://dx.doi.org/10.2174/157489207782497172
DOI https://dx.doi.org/10.2174/157489207782497172 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lipidomic Analysis of Glioblastoma Multiforme Using Mass Spectrometry
Current Metabolomics Meet Our Editorial Board Member
Current Medicinal Chemistry Metallothioneins and Cancer
Current Protein & Peptide Science Mitochondrial Proteases as Emerging Pharmacological Targets
Current Pharmaceutical Design Cytotoxicity and Molecular Targeting Study of Novel 2-Chloro-3- substituted Quinoline Derivatives as Antitumor Agents
Letters in Drug Design & Discovery Novel Methods for the Non-Invasive Administration of DNA Therapeutics and Vaccines
Current Drug Delivery Recent Advances in Copper Radiopharmaceuticals
Current Radiopharmaceuticals Inhibition of Tumor Cells Proliferation and Migration by the Flavonoid Furin Inhibitor Isolated From Oroxylum indicum
Current Medicinal Chemistry Natural Products Triggering Biological Targets- A Review of the Anti-Inflammatory Phytochemicals Targeting the Arachidonic Acid Pathway in Allergy Asthma and Rheumatoid Arthritis
Current Drug Targets Actinium-225 in Targeted Alpha-Particle Therapeutic Applications
Current Radiopharmaceuticals Electrochemically Driven Supramolecular Interaction of Quinones and Ferrocifens: An Example of Redox Activation of Bioactive Compounds
Current Topics in Medicinal Chemistry Prospects of miRNA-Based Therapy for Pancreatic Cancer
Current Drug Targets Biological Rationales and Clinical Applications of Temperature Controlled Hyperthermia - Implications for Multimodal Cancer Treatments
Current Medicinal Chemistry Indoor Dust Levels of Perfluoroalkyl Substances (PFASs) and the Role of Ingestion as an Exposure Pathway: A Review
Current Organic Chemistry Regulation of the PI3K-Akt Network: Current Status and a Promise for the Treatment of Human Diseases
Current Signal Transduction Therapy New Insights in Drug-Induced Mitochondrial Toxicity
Current Pharmaceutical Design Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies
Mini-Reviews in Medicinal Chemistry Soy Saponins and the Anticancer Effects of Soybeans and Soy-Based Foods
Current Medicinal Chemistry - Anti-Cancer Agents Alkylphospholipids are Signal Transduction Modulators with Potential for Anticancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Properties and Recent Advantages of N,N’-dialkylimidazolium-ion Liquids Application in Electrochemistry
Current Analytical Chemistry